MOC31 - Revision history

Michael at 16:30, 15 May 2016

2016-05-15T16:30:17Z

← Older revision		Revision as of 16:30, 15 May 2016
Line 14:		Line 14:
	==See also==		==See also==
	*[[Immunohistochemistry]].		*[[Immunohistochemistry]].
			*[[Ber-EP4]].

	==References==		==References==

Michael at 17:09, 4 February 2015

2015-02-04T17:09:00Z

← Older revision		Revision as of 17:09, 4 February 2015
Line 1:		Line 1:
	'''MOC31''' is an [[immunostain]].		'''MOC31''' is an [[immunostain]]. The antibody is directed against the epithelial cell adhesion molecule (Ep-CAM, TACSTD1).<ref name=pmid19391212/>

	It is ~~useful for differentiating [[hepatocellular carcinoma]] from [[cholangiocarcinoma]] and [[liver metastases]]~~.<ref name=pmid10937059>{{Cite journal \| last1 = Proca \| first1 = DM. \| last2 = Niemann \| first2 = TH. \| last3 = Porcell \| first3 = AI. \| last4 = DeYoung \| first4 = BR. \| title = MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers. \| journal = Appl Immunohistochem Mol Morphol \| volume = 8 \| issue = 2 \| pages = 120-5 \| month = Jun \| year = 2000 \| doi = \| PMID = 10937059 }}</~~ref~~>

	==Negative==		==Negative==
	*[[Hepatocellular carcinoma]].<ref name=pmid10937059/>		*[[Hepatocellular carcinoma]].<ref name=pmid10937059>{{Cite journal \| last1 = Proca \| first1 = DM. \| last2 = Niemann \| first2 = TH. \| last3 = Porcell \| first3 = AI. \| last4 = DeYoung \| first4 = BR. \| title = MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers. \| journal = Appl Immunohistochem Mol Morphol \| volume = 8 \| issue = 2 \| pages = 120-5 \| month = Jun \| year = 2000 \| doi = \| PMID = 10937059 }}</ref>
	*[[Malignant mesothelioma\|Malignant epithelioid mesothelioma]] - usually negative.<ref name=pmid9490276/>		*[[Malignant mesothelioma\|Malignant epithelioid mesothelioma]] - usually negative.<ref name=pmid9490276/>

Michael: /* Positive */

2015-02-04T17:04:48Z

Positive

← Older revision		Revision as of 17:04, 4 February 2015
Line 11:		Line 11:
	*[[Liver metastases]].<ref name=pmid10937059/>		*[[Liver metastases]].<ref name=pmid10937059/>
	*[[Lung adenocarcinoma]].<ref name=pmid9490276>{{Cite journal \| last1 = Ordóñez \| first1 = NG. \| title = Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. \| journal = Hum Pathol \| volume = 29 \| issue = 2 \| pages = 166-9 \| month = Feb \| year = 1998 \| doi = \| PMID = 9490276 }}</ref>		*[[Lung adenocarcinoma]].<ref name=pmid9490276>{{Cite journal \| last1 = Ordóñez \| first1 = NG. \| title = Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. \| journal = Hum Pathol \| volume = 29 \| issue = 2 \| pages = 166-9 \| month = Feb \| year = 1998 \| doi = \| PMID = 9490276 }}</ref>
			*[[Invasive ductal carcinoma of the breast]].<ref name=pmid19391212>{{Cite journal \| last1 = Pai \| first1 = RK. \| last2 = West \| first2 = RB. \| title = MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive lobular and ductal carcinoma of the breast: a tissue microarray study. \| journal = Appl Immunohistochem Mol Morphol \| volume = 17 \| issue = 3 \| pages = 202-6 \| month = May \| year = 2009 \| doi = \| PMID = 19391212 }}</ref>
			*[[Invasive lobular carcinoma]].<ref name=pmid19391212/>

	==See also==		==See also==

Michael at 17:01, 4 February 2015

2015-02-04T17:01:59Z

← Older revision		Revision as of 17:01, 4 February 2015
Line 5:		Line 5:
	==Negative==		==Negative==
	*[[Hepatocellular carcinoma]].<ref name=pmid10937059/>		*[[Hepatocellular carcinoma]].<ref name=pmid10937059/>
			*[[Malignant mesothelioma\|Malignant epithelioid mesothelioma]] - usually negative.<ref name=pmid9490276/>

	==Positive==		==Positive==
	*[[Cholangiocarcinoma]].<ref name=pmid10937059/>		*[[Cholangiocarcinoma]].<ref name=pmid10937059/>
	*[[Liver metastases]].<ref name=pmid10937059/>		*[[Liver metastases]].<ref name=pmid10937059/>
			*[[Lung adenocarcinoma]].<ref name=pmid9490276>{{Cite journal \| last1 = Ordóñez \| first1 = NG. \| title = Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. \| journal = Hum Pathol \| volume = 29 \| issue = 2 \| pages = 166-9 \| month = Feb \| year = 1998 \| doi = \| PMID = 9490276 }}</ref>

	==See also==		==See also==

Michael: create

2015-02-04T16:57:59Z

create

New page

'''MOC31''' is an [[immunostain]].

It is useful for differentiating [[hepatocellular carcinoma]] from [[cholangiocarcinoma]] and [[liver metastases]].<ref name=pmid10937059>{{Cite journal | last1 = Proca | first1 = DM. | last2 = Niemann | first2 = TH. | last3 = Porcell | first3 = AI. | last4 = DeYoung | first4 = BR. | title = MOC31 immunoreactivity in primary and metastatic carcinoma of the liver. Report of findings and review of other utilized markers. | journal = Appl Immunohistochem Mol Morphol | volume = 8 | issue = 2 | pages = 120-5 | month = Jun | year = 2000 | doi = | PMID = 10937059 }}</ref>

==Negative==
*[[Hepatocellular carcinoma]].<ref name=pmid10937059/>

==Positive==
*[[Cholangiocarcinoma]].<ref name=pmid10937059/>
*[[Liver metastases]].<ref name=pmid10937059/>

==See also==
*[[Immunohistochemistry]].

==References==
{{Reflist|1}}

[[Category:Immunohistochemistry]]